Conditions: Acute Myelogenous Leukemia
Keywords: acute myelogenous leukemia interleukin-2
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 18
Healthy volunteers: no

Brief summary:
Assess the immunotherapy benefit of interleukin-2 in acute myelogenous leukemia treatment during lymphocyte recovery.

Detailed description:
Upon lymphocyte recovery after myeloablative induction standard chemotherapy pulse Interleukin-2 administered

Arms:
arm 1: interleukin-2 therapy during lymphocyte recovery

Interventions: intervention 1: Interleukin-2
Intervention descriptions: intervention 1: Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days

Protocol document: